WO2015056094A3 - Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent - Google Patents

Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent Download PDF

Info

Publication number
WO2015056094A3
WO2015056094A3 PCT/IB2014/002501 IB2014002501W WO2015056094A3 WO 2015056094 A3 WO2015056094 A3 WO 2015056094A3 IB 2014002501 W IB2014002501 W IB 2014002501W WO 2015056094 A3 WO2015056094 A3 WO 2015056094A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
analgesic agent
trpa1 antagonist
patent application
present patent
Prior art date
Application number
PCT/IB2014/002501
Other languages
French (fr)
Other versions
WO2015056094A2 (en
Inventor
Srinivas Gullapalli
Praveen Kumar GUPTA
Maulik Nitinkumar GANDHI
Original Assignee
Glenmark Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals S.A. filed Critical Glenmark Pharmaceuticals S.A.
Priority to CA2926389A priority Critical patent/CA2926389A1/en
Priority to MX2016004741A priority patent/MX2016004741A/en
Priority to JP2016523322A priority patent/JP2016537322A/en
Priority to AU2014335868A priority patent/AU2014335868A1/en
Priority to CN201480067832.3A priority patent/CN105813638A/en
Priority to EP14819068.9A priority patent/EP3057583A2/en
Priority to RU2016115093A priority patent/RU2016115093A/en
Publication of WO2015056094A2 publication Critical patent/WO2015056094A2/en
Publication of WO2015056094A3 publication Critical patent/WO2015056094A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject.
PCT/IB2014/002501 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent WO2015056094A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2926389A CA2926389A1 (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
MX2016004741A MX2016004741A (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent.
JP2016523322A JP2016537322A (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic
AU2014335868A AU2014335868A1 (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
CN201480067832.3A CN105813638A (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent
EP14819068.9A EP3057583A2 (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
RU2016115093A RU2016115093A (en) 2013-10-15 2014-10-14 PHARMACEUTICAL COMPOSITION CONTAINING TRPA1 ANTAGONIST AND ANALGETIC AGENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3247/MUM/2013 2013-10-15
IN3247MU2013 2013-10-15

Publications (2)

Publication Number Publication Date
WO2015056094A2 WO2015056094A2 (en) 2015-04-23
WO2015056094A3 true WO2015056094A3 (en) 2015-08-13

Family

ID=52146548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/002501 WO2015056094A2 (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent

Country Status (9)

Country Link
US (1) US9532988B2 (en)
EP (1) EP3057583A2 (en)
JP (1) JP2016537322A (en)
CN (1) CN105813638A (en)
AU (1) AU2014335868A1 (en)
CA (1) CA2926389A1 (en)
MX (1) MX2016004741A (en)
RU (1) RU2016115093A (en)
WO (1) WO2015056094A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
CA3000398A1 (en) * 2015-09-30 2017-04-06 George Edward Hoag Topical analgesic pain relief formulations, manufacture and methods of use thereof
GB201520057D0 (en) * 2015-11-13 2015-12-30 Ucl Business Plc New therapeutic approaches for demyelinating diseases such as multiple sclerosis
EP3439656A4 (en) * 2016-04-07 2020-03-11 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
CN106243096B (en) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 The new application of tricyclic drugs
FR3114235A1 (en) 2020-09-18 2022-03-25 Université Grenoble Alpes INHIBITION OF ASTROCYTIC TRPA1 CHANNEL AS A NEW NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE
CN112438970B (en) * 2020-11-20 2023-04-21 南方医科大学南方医院 New application of milnacipran or/and pharmaceutical salt of milnacipran
IT202100015098A1 (en) 2021-06-09 2022-12-09 Flonext S R L TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE DISEASES OF THE RETINA
CN115778945A (en) * 2023-01-31 2023-03-14 广州帝奇医药技术有限公司 Composition and application thereof in preparing medicine for treating neuropathic pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010109334A2 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Thienopyrimidinedione derivatives as trpa1 modulators
US20120157411A1 (en) * 2010-12-20 2012-06-21 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpai antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
TWI649092B (en) 2005-12-22 2019-02-01 海卓勒生物科學公司 Compound for regulating TRPA1 function
AR065081A1 (en) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc FUSIONATED QUINAZOLINONA AND PIRIMIDONA COMPOUNDS AND PHARMACEUTICAL COMPOSITION
US8163761B2 (en) 2007-06-22 2012-04-24 Hydra Biosciences, Inc. Methods and compositions for treating disorders
CN101959511A (en) 2008-01-04 2011-01-26 雅培制药有限公司 The TRPA1 antagonist
WO2009144548A1 (en) 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
EA023857B1 (en) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Fused pyrimidine-dione derivatives as trpa1 modulators
KR20120001746A (en) 2009-03-23 2012-01-04 그렌마크 파머수티칼스 에스. 아. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
WO2010125469A1 (en) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
US8614201B2 (en) 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
US8829196B2 (en) 2009-10-07 2014-09-09 Merck Sharp & Dohme Corp. TRPA1 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010109334A2 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Thienopyrimidinedione derivatives as trpa1 modulators
US20120157411A1 (en) * 2010-12-20 2012-06-21 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpai antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERICA S SCHWARTZ ET AL: "Synergistic Role of TRPV1 and TRPA1 in Pancreatic Pain and Inflammation", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 140, no. 4, 20 December 2010 (2010-12-20), pages 1283 - 1291.e2, XP028156895, ISSN: 0016-5085, [retrieved on 20101224], DOI: 10.1053/J.GASTRO.2010.12.033 *
PIER GIOVANNI BARALDI ET AL: "Transient Receptor Potential Ankyrin 1 (TRPA1) Channel as Emerging Target for Novel Analgesics and Anti-Inflammatory Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 14, 22 July 2010 (2010-07-22), pages 5085 - 5107, XP055031281, ISSN: 0022-2623, DOI: 10.1021/jm100062h *

Also Published As

Publication number Publication date
MX2016004741A (en) 2016-07-26
RU2016115093A (en) 2017-11-21
CA2926389A1 (en) 2015-04-23
EP3057583A2 (en) 2016-08-24
AU2014335868A1 (en) 2016-05-05
US9532988B2 (en) 2017-01-03
US20150105406A1 (en) 2015-04-16
CN105813638A (en) 2016-07-27
WO2015056094A2 (en) 2015-04-23
JP2016537322A (en) 2016-12-01

Similar Documents

Publication Publication Date Title
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2015008628A (en) Boronic acid derivatives and therapeutic uses thereof.
PH12016501122A1 (en) Delayed release compositions of linaclotide
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
HK1215567A1 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
MX2015009106A (en) Solid solution compositions and use in severe pain.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
UA115357C2 (en) Pyridin-4-yl derivatives
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2014153495A9 (en) Novel stat3 inhibitors
EP3012256A4 (en) Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof
EP2987786A4 (en) Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2014146111A3 (en) Analgesic compounds and methods of use
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
MX357704B (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
MX368640B (en) PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION and PAIN.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2926389

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014819068

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014819068

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/004741

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016523322

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016008119

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014335868

Country of ref document: AU

Date of ref document: 20141014

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016115093

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14819068

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016008119

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160412